3470-55-1

Usage

Uses

Used in Pharmaceutical Industry:
2-amino-6,7,8,9-tetrahydrobenzo[7]annulen-5-one is used as a potential pharmaceutical agent for its ability to interact with biological systems. Its unique molecular structure allows it to potentially exhibit therapeutic effects, making it a candidate for the development of new drugs.
Used in Medicinal Chemistry Research:
In the realm of medicinal chemistry, 2-amino-6,7,8,9-tetrahydrobenzo[7]annulen-5-one serves as a subject of study for its potential pharmacological properties. Researchers are interested in understanding how 2-amino-6,7,8,9-tetrahydrobenzo[7]annulen-5-one can be utilized to create novel therapeutic agents or enhance existing ones.

Upstream product

• 24127-36-4 2-chloro-6,7,8,9-tetrahydro-5H-benzocycloheptene-5-one 
• 93188-08-0 4-<3-Acetamino-benzoyl>-buttersaeure 
• 95207-74-2 2-(N-acetyl)amino-6,7,8,9-tetrahydrobenzo-cyclohepten-5-one 
• 93431-20-0 5-(3-acetamidophenyl)pentanoic acid 

Downstream Products

• 1049666-14-9 2,6-difluoro-N-(5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-benzamide 
• 24127-36-4 2-chloro-6,7,8,9-tetrahydro-5H-benzocycloheptene-5-one 
• 954152-10-4 C₂₅H₂₅NO 
• 3470-51-7 2-hydroxy-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-one 

Relevant academic research and scientific papers

SUBSTITUTED POLYCYCLIC ANTIBACTERIAL COMPOUNDS

The present description relates to substituted polycyclic compounds and forms and pharmaceutical compositions thereof and methods of using such compounds, forms or compositions thereof for treating or ameliorating Neisseria gonorrhoeae and Neisseria meningiditis.

HMG-CoA reductase inhibitors

Compounds are provided of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and trea

Selective κ-opioid agonists: Synthesis and structure-activity relationships of piperidines incorporating an oxo-containing acyl group

This study describes the synthesis and the structure-activity relationships (SARs) of the (S)-(-)-enantiomers of a novel class of 2- (aminomethyl)piperidine derivatives, using κ-opioid binding affinity and antinociceptive potency as the indices of biological activity. Compounds incorporating the 1-tetralon-6-ylacetyl residue (30 and 34-45) demonstrated an in vivo antinociceptive activity greater than predicted on the basis of their κ-binding affinities. In particular, (2S)-2-[(dimethylamino)methyl]- 1-[(5,6,7,8-tetrahydro-5-oxo-2-naphthyl)acetyl]piperidine (34) was found to have a potency similar to spiradoline in animal models of antinociception after subcutaneous administration, with ED50s of 0.47 and 0.73 μmol/kg in the mouse and in the rat abdominal constriction tests, respectively. Further in vivo studies in mice and/or rats revealed that compound 34, compared to other selective κ-agonists, has a reduced propensity to cause a number of κ-related side effects, including locomotor impairment/sedation and diuresis, at antinociceptive doses. For example, it has an ED50 of 26.5 μmol/kg sc in the rat rotarod model, exhibiting a ratio of locomotor impairment/sedation vs analgesia of 36. Possible reasons for this differential activity and its clinical consequence are discussed.